skip to main content
Language:
Show Results with:

9 results  for Everything in this catalogue

Sort by: Sort by: relevanceOr hit Enter to replace sort method
Refined by: additional feature: Abstract remove author: White, H. D. remove subject: Pharmaceutical chemistry remove author: Harrington, R. A. remove
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Age, treatment, and outcomes in high-risk non ST-segment elevation acute coronary syndrome patients: Insights from the EARLY ACS trial
Age, treatment, and outcomes in high-risk non ST-segment elevation acute coronary syndrome patients: Insights from the EARLY ACS trial
Material Type:
Article 		Add to My workspace

Age, treatment, and outcomes in high-risk non ST-segment elevation acute coronary syndrome patients: Insights from the EARLY ACS trial

Lopes, R. D. et al.

International journal of cardiology. VOL 167; NUMBER 6, ; 2013, 2580-2587 -- Elsevier Science B.V., Amsterdam. Part 6; (pages 2580-2587) -- 2013

Online access

2
Usefulness and Safety of Vorapaxar in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention (from the TRACER Trial)
Usefulness and Safety of Vorapaxar in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention (from the TRACER Trial)
Material Type:
Article 		Add to My workspace

Usefulness and Safety of Vorapaxar in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention (from the TRACER Trial)

Valgimigli, M. et al.

The American journal of cardiology. VOL 114; NUMBER 5, ; 2014, 665-673 -- Elsevier Science B. V., Amsterdam Part 5; (pages 665-673) -- 2014

Online access

3
Vorapaxar in patients with peripheral artery disease and acute coronary syndrome: Insights from Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER)
Vorapaxar in patients with peripheral artery disease and acute coronary syndrome: Insights from Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER)
Material Type:
Article 		Add to My workspace

Vorapaxar in patients with peripheral artery disease and acute coronary syndrome: Insights from Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER)

Jones, W. S. et al.

American heart journal. VOL 168; NUMBER 4, ; 2014, 588-596 -- Elsevier Science B.V., Amsterdam Part 4; (pages 588-596) -- 2014

Check library holdings

4
Reduced immediate ischemic events with cangrelor in PCI: A pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction
Reduced immediate ischemic events with cangrelor in PCI: A pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction
Material Type:
Article 		Add to My workspace

Reduced immediate ischemic events with cangrelor in PCI: A pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction

White, H. D. et al.

American heart journal. VOL 163; NUMBER 2, ; 2012, 182-190.e4 -- Elsevier Science B.V., Amsterdam Part: Part 2; (pages 182-190.e4) -- 2012

Online access

5
Enoxaparin Versus Unfractionated Heparin in Elective Percutaneous Coronary Intervention:1-Year Results From the STEEPLE (SafeTy and Efficacy of Enoxaparin in Percutaneous coronary intervention patients, an internationaL randomized Evaluation) Trial
Enoxaparin Versus Unfractionated Heparin in Elective Percutaneous Coronary Intervention:1-Year Results From the STEEPLE (SafeTy and Efficacy of Enoxaparin in Percutaneous coronary intervention patients, an internationaL randomized Evaluation) Trial
Material Type:
Article 		Add to My workspace

Enoxaparin Versus Unfractionated Heparin in Elective Percutaneous Coronary Intervention:1-Year Results From the STEEPLE (SafeTy and Efficacy of Enoxaparin in Percutaneous coronary intervention patients, an internationaL randomized Evaluation) Trial

Montalescot, G. et al.

JACC. Cardiovascular interventions. VOL 2; NUMBER 11, ; 2009, 1083-1091 -- ELSEVIER SCIENCE B. V., AMSTERDAM (pages 1083-1091) -- 2009

Online access

6
Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non–ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial
Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non–ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial
Material Type:
Article 		Add to My workspace

Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non–ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial

White, H. D. et al.

American heart journal. VOL 152; NUMBER 6, ; 2006, 1042-1050 -- Elsevier Science B.V., Amsterdam (pages 1042-1050) -- 2006

Online access

7
Elevated creatine kinase-MB with normal creatine kinase predicts worse outcomes in patients with acute coronary syndromes: Results from 4 large clinical trials
Elevated creatine kinase-MB with normal creatine kinase predicts worse outcomes in patients with acute coronary syndromes: Results from 4 large clinical trials
Material Type:
Article 		Add to My workspace

Elevated creatine kinase-MB with normal creatine kinase predicts worse outcomes in patients with acute coronary syndromes: Results from 4 large clinical trials

Galla, J. M. et al.

American heart journal. VOL 151; NUMBER 1, ; 2006, 16-24 -- Elsevier Science B.V., Amsterdam (pages 16-24) -- 2006

Online access

8
Incidence, distribution, and prognostic impact of occluded culprit arteries among patients with non–ST-elevation acute coronary syndromes undergoing diagnostic angiography
Incidence, distribution, and prognostic impact of occluded culprit arteries among patients with non–ST-elevation acute coronary syndromes undergoing diagnostic angiography
Material Type:
Article 		Add to My workspace

Incidence, distribution, and prognostic impact of occluded culprit arteries among patients with non–ST-elevation acute coronary syndromes undergoing diagnostic angiography

Wang, T. Y. et al.

American heart journal. VOL 157; NUMBER 4, ; 2009, 716-723 -- Elsevier Science B.V., Amsterdam (pages 716-723) -- 2009

Online access

9
International Variation in the Use of Blood Transfusion in Patients With Non–ST-Segment Elevation Acute Coronary Syndromes
International Variation in the Use of Blood Transfusion in Patients With Non–ST-Segment Elevation Acute Coronary Syndromes
Material Type:
Article 		Add to My workspace

International Variation in the Use of Blood Transfusion in Patients With Non–ST-Segment Elevation Acute Coronary Syndromes

Rao, S. V. et al.

The American journal of cardiology. VOL 101; NUMBER 1, ; 2008, 25-29.e2 -- Elsevier Science B.V., Amsterdam. (pages 25-29.e2) -- 2008

Online access

9 results  for Everything in this catalogue

Sort by: Sort by: relevanceOr hit Enter to replace sort method

Refine Search Results

Try a new search

Ignore my search and look for everything

by this Author/Contributor:

  1. Harrington, R. A.
  2. White, H. D.
  3. Armstrong, P. W.
  4. Van De Werf, F.
  5. Tricoci, P.

on this subject:

  1. Medicine
  2. Biotechnology

All text is © British Library Board and is available under a Creative Commons Attribution Licence, except where otherwise stated.

P3

Searching Remote Databases, Please Wait